TIME IS LIFE
DEAD

Serial Number

77190373

Owner

Paion Deutschland GmbH

Attorney

GARY D. KRUGMAN

Filing Date

May 25, 2007

Add to watchlist:

No watchlists yet
View on USPTO

TIME IS LIFE Trademark

Serial Number: 77190373

TIME IS LIFE is a trademark filed by Paion Deutschland GmbH on May 25, 2007. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Paion Deutschland GmbH (11 trademarks)

Martinstr. 10-12
52062 Aachen , DE

Entity Type: 99

Trademark Details

Filing Date

May 25, 2007

Registration Date

Not Registered

Published for Opposition

August 3, 2010

Goods & Services

Educational services, namely, providing seminars and workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, and gendiagnostics

Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents

Computerized database management, namely, processing data for third parties in the field of drug development

Reagents for scientific or medical research use; diagnostic preparations or reagents for scientific or research use, biochemical reagents for scientific or medical research use; biochemical diagnostic preparations or reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use

Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting medical diagnostic tests and blood specimen analysis of the human blood clotting system; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis and hemofiltration

Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; services of a biotechnological laboratory, namely, conducting laboratory research for others in the field of drug research and development; pharmaceutical research consulting, namely, performing pre-clinical studies; performing quality control for others; preparation of expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry; product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic research services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical research namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; biochemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment; scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 2, 2011 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 2, 2011 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 28, 2010 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 3, 2010 NPUB
PUBLISHED FOR OPPOSITION
Aug 3, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 29, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 28, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 18, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 18, 2010 CRFA
ASSIGNED TO LIE
Jun 18, 2010 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2009 GNRN
NON-FINAL ACTION E-MAILED
Dec 9, 2009 GNRT
NON-FINAL ACTION WRITTEN
Dec 9, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 19, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 19, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 30, 2009 GNRN
NON-FINAL ACTION E-MAILED
May 30, 2009 GNRT
NON-FINAL ACTION WRITTEN
May 30, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 27, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 26, 2009 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 26, 2009 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 9, 2009 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 9, 2009 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 9, 2009 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 6, 2009 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 6, 2008 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 6, 2008 GNSL
SUSPENSION LETTER WRITTEN
Oct 6, 2008 CNSL
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 22, 2008 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 21, 2008 RCSC
ASSIGNED TO LIE
Mar 20, 2008 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 13, 2007 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 13, 2007 GNSL
SUSPENSION LETTER WRITTEN
Sep 13, 2007 CNSL
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 7, 2007 GNRN
NON-FINAL ACTION E-MAILED
Sep 7, 2007 GNRT
NON-FINAL ACTION WRITTEN
Sep 7, 2007 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2007 DOCK
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 16, 2007 PARI
NEW APPLICATION ENTERED
Jun 1, 2007 NWAP